Exact Sciences - EXAS Stock Forecast, Price & News

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. StockNews.com upgraded Exact Sciences from a "sell" rating to a "hold" rating in a report on Tuesday, July 26th. Benchmark cut their price target on Exact Sciences to $54.00 in a report on Tuesday. Cowen cut their price target on Exact Sciences from $83.00 to $67.00 and set an "outperform" rating on the stock in a report on Wednesday, August 3rd. The Goldman Sachs Group cut their price target on Exact Sciences from $100.00 to $85.00 and set a "buy" rating on the stock in a report on Tuesday, April 19th. Finally, Citigroup lowered their price objective on Exact Sciences from $65.00 to $50.00 and set a "neutral" rating for the company in a research report on Wednesday, August 3rd. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $71.00.

Exact Sciences Stock Performance

Shares of EXAS traded up $2.08 during trading hours on Wednesday, hitting $45.13. The stock had a trading volume of 3,151,778 shares, compared to its average volume of 2,117,829. The firm has a 50-day moving average price of $44.30 and a 200 day moving average price of $58.46. Exact Sciences has a fifty-two week low of $35.34 and a fifty-two week high of $108.99. The firm has a market capitalization of $7.99 billion, a price-to-earnings ratio of -10.18 and a beta of 1.32. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.23 and a current ratio of 2.48.

Insider Buying and Selling

In other news, Director Katherine S. Zanotti sold 4,608 shares of the company's stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $45.14, for a total transaction of $208,005.12. Following the completion of the transaction, the director now directly owns 60,318 shares of the company's stock, valued at approximately $2,722,754.52. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, Director Katherine S. Zanotti sold 4,608 shares of the company's stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $45.14, for a total transaction of $208,005.12. Following the completion of the transaction, the director now owns 60,318 shares in the company, valued at approximately $2,722,754.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Katherine S. Zanotti sold 1,086 shares of the firm's stock in a transaction dated Thursday, June 30th. The shares were sold at an average price of $40.13, for a total transaction of $43,581.18. Following the completion of the transaction, the director now directly owns 60,318 shares in the company, valued at $2,420,561.34. The disclosure for this sale can be found here. In the last 90 days, insiders sold 5,701 shares of company stock valued at $251,872. 1.30% of the stock is owned by company insiders.